Copertina

Distance to CAR‐T Treatment Center Does Not Impede Delivery

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Xiu Xia Sherry Tan, Melissa T. Maltez, Ranjeeta Mallick, Linda Hamelin, Sheryl McDiarmid, Carolina Cieniak, Matthew Granger, Christopher Bredeson, Michael Kennah, Harold L. Atkins, Natasha Kekre
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	European Journal of Haematology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Late Immune Effector Cell‐Associated Hematologic Toxicity After CD19 CAR ‐T Therapy: Incidence, Clinical Course, and Resource Utilization
di: Philippe Giguère, et al.
Pubblicazione: (2026)

Outcomes with low dose anti‐thymocyte globulin based graft versus host disease prophylaxis after mismatched unrelated donor allogeneic hematopoietic cell transplantation
di: Hafsah Chalchal, et al.
Pubblicazione: (2024)

The CAR T‐cell race: The rules of the game
di: Adriana Balduzzi
Pubblicazione: (2024)

Coagulopathy in CAR‐T: Critical concern or mere blip?
di: Eugenio Galli, et al.
Pubblicazione: (2024)

Are we there yet? CAR ‐T therapy in multiple myeloma
di: Eitan Mirvis, et al.
Pubblicazione: (2024)

CCR5 predicts neurotoxicity in CAR‐T‐cell therapy
di: Ayal Rozenberg, et al.
Pubblicazione: (2025)

Success of donor‐derived CAR‐T cells after failure of autologous CD19 CAR‐T cells (tisagenlecleucel) in B‐cell acute lymphoblastic leukaemia
di: Marie Emilie Dourthe, et al.
Pubblicazione: (2024)

Lymphocyte dynamics after CAR ‐T therapy for non‐Hodgkin lymphoma
di: Sarah Dingli, et al.
Pubblicazione: (2026)

Management of immunosuppression in post‐transplant lymphoproliferative disorders treated with CAR T cells
di: Nathacha Jimkap, et al.
Pubblicazione: (2024)

Real‐world experience with CAR‐T therapy in relapsed and refractory follicular lymphoma
di: Nicolás Triantafilo, et al.
Pubblicazione: (2025)

Coagulation abnormalities associated with CAR‐T‐cell therapy in haematological malignancies: A review
di: Xiaojuan Peng, et al.
Pubblicazione: (2024)

The interleukin‐6 connection: Understanding cytomegalovirus reactivation following CAR ‐T‐cell therapy
di: Linghao Li, et al.
Pubblicazione: (2025)

Tandem combination of ASCT and CAR T‐cell therapy in highly refractory CNS lymphomas
di: Lydia Montes, et al.
Pubblicazione: (2025)

Robust CAR T‐cell expansion and superior outcomes in DLBCL patients in complete response at infusion
di: Ryo Hanajiri, et al.
Pubblicazione: (2025)

Predicting therapy‐related myeloid neoplasms after CAR‐T with the Clonal Haematopoiesis Risk Score (CHRS)
di: Eugenio Galli, et al.
Pubblicazione: (2024)

Optimizing activation and culture conditions for the production of cord blood‐derived CAR ‐T and natural killer cells
di: Naokazu Nakamura, et al.
Pubblicazione: (2025)

Microbiome‐Based Modeling of CAR ‐T Therapy Response in Lymphoma: Insights From Shotgun Metagenomics Sequencing
di: Rafael Hernani, et al.
Pubblicazione: (2026)

Ocular adverse events following CAR‐T cell therapy: A pharmacovigilance study and systematic review
di: Connor Frey, et al.
Pubblicazione: (2024)

CAR T access and outcomes in large B‐cell lymphoma according to ethnicity and socioeconomic deprivation in the UK
di: Diana Dragoi, et al.
Pubblicazione: (2025)

Frail is not fail: Limited impact of comorbidities on non‐relapse mortality and safety in patients with LBCL treated with CAR‐T
di: Eugenio Galli, et al.
Pubblicazione: (2025)

Management of Primary Refractory Diffuse Large B‐Cell Lymphoma in Patients Unsuitable for CAR T‐Cell Therapy
di: Santino Caserta, et al.
Pubblicazione: (2026)

Is universal CAR T‐cell referral absolutely required for transplant‐ineligible patients with primary refractory or early relapsed DLBCL ?
di: Maria Dimou, et al.
Pubblicazione: (2026)

Metformin augments GPRC5D in multiple myeloma and enhances the efficacy of GPRC5D‐CAR T cells
di: Xiaoli Hu, et al.
Pubblicazione: (2024)

Real‐World Experience With a ZUMA ‐1 Cohort 4 Adopted Approach to CRS and ICANS in CAR ‐T Recipients
di: Chiranjeevi Sainatham, et al.
Pubblicazione: (2026)

Consistent ex vivo cell proliferation during manufacturing predicts favourable outcomes post‐CAR‐T‐cell therapy
di: Tomoyasu Jo, et al.
Pubblicazione: (2025)

Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T‐cells
di: Iñaki Ortiz de Landazuri, et al.
Pubblicazione: (2024)

Outcomes of CD19 CAR‐T therapy in central nervous system lymphoma: Insights from a multicentre experience
di: Giulio Cassanello, et al.
Pubblicazione: (2025)

Atrial arrhythmias following CAR‐chimeric antigen receptor T‐cell therapy: Incidence, risk factors and biomarker profile
di: Roni Shouval, et al.
Pubblicazione: (2024)

The Amyloidosis Intersection: Dual Amyloid Types in a Single Host
di: Soumya Ramireddy, et al.
Pubblicazione: (2025)

Transient imaging changes accompany ‘spinal ICANS ’ following CAR T‐cell therapy for large B‐cell lymphoma in adults
di: Frederick W. Vonberg, et al.
Pubblicazione: (2025)

Salvage Therapies After Anti‐BCMA CAR‐T Failure in Patients With Multiple Myeloma: A Meta‐Analysis of Response Rates
di: Jaromir Tomasik, et al.
Pubblicazione: (2026)

mRNA‐laden lipid nanoparticle‐enabled humanized CD19 CAR‐T‐cell engineering for the eradication of leukaemic cells
di: Zhaozhao Chen, et al.
Pubblicazione: (2025)

Anti‐CD19 CAR T‐cell therapy for patients with Richter transformation: A LYSA study from the DESCAR‐T registry
di: Hedi Bensaber, et al.
Pubblicazione: (2025)

Decreased renal function predicts severe cytokine release syndrome after CAR ‐T‐cell therapy for large B‐cell lymphoma
di: Yasuyuki Arai, et al.
Pubblicazione: (2026)

Predictive value of MRD monitoring by BCR clonality in the ZUMA ‐7 randomized clinical trial for CAR T therapy in r/r lymphoma
di: Brodie Miles, et al.
Pubblicazione: (2026)

Hepatitis E virus infection after CAR T‐cell treatment: An important complication in patients already facing significant health challenges
di: Vincent Mallet, et al.
Pubblicazione: (2024)

Efficacy and Safety of Bendamustine Versus Fludarabine and Cyclophosphamide as Lymphodepleting Regimens for CAR ‐T Therapy in Hematological Malignancies: A Systematic Review and Meta‐Analysis
di: Akihiro Miyashita, et al.
Pubblicazione: (2026)

Secondary primary malignancies after CD‐19 directed CAR‐T‐cell therapy in lymphomas: A report from the Italian CART‐SIE study
di: Angelica Barone, et al.
Pubblicazione: (2024)

Chimeric antigen receptor copies in cell‐free DNA predict relapse in aggressive B‐cell lymphoma patients treated with CAR T‐cell therapy
di: Ismael de la Iglesia‐San Sebastián, et al.
Pubblicazione: (2024)

In response to Bergonzi et al.: Azacitidine–ruxolitinib combination therapy may permit dose reduction in VEXAS syndrome
di: Jeremiah Tan, et al.
Pubblicazione: (2026)